Extended Ambulatory Monitoring Improves Risk Stratification in Hypertrophic Cardiomyopathy

Atlantic Health System

Status: Unknown

Conditions: Hypertrophic Cardiomyopathy

Treatments: Device: Extended Cardiac Monitoring

Study type: Observational

Funder types: Other

Identifiers

NCT03182153

SEEQ

Details and patient eligibility

About

Eligible subjects will wear 4 consecutive external monitoring devices for a total of 28 days of monitoring.

Full description

Eligible subjects will be monitored with a SEEQ device. The SEEQ device is a patch-like device that is worn externally on the chest and continuously monitors heart rhythm. Each device is worn for seven days and replaced with additional devices for a total of 28 days of monitoring. Subjects will return the SEEQ equipment at the end of the monitoring period. Subjects will be contacted by telephone or seen at the clinic approximately 60 days from the first day of monitoring. Information will be gathered about medications and any cardiac interventions the subject may have had.

Subjects will again be contacted by telephone or seen in the clinic approximately 1 year from study start. Information will be gathered about general health, changes in medications, and cardiac interventions or events. Cardiac testing results will be reviewed.

Enrollment: 83 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Clinical diagnosis of HCM Scheduled for routine ambulatory monitoring for risk stratification Followed at the Chanin T. Mast HCM Center at Morristown Medical Center

Exclusion criteria

Prior implantation of an ICD History of persistent/permanent atrial fibrillation (AF)

Trial design

83 participants in 1 patient group

Enrolled subjects

Description:

Subjects who are diagnosed with HCM and require routine extended cardiac monitoring for risk stratification of sudden cardiac death. All subjects will receive 28 days of external cardiac monitoring.

Treatment:

Device: Extended Cardiac Monitoring